Poseida Therapeutics, Inc. (PSTX)
Jan 8, 2025 - PSTX was delisted (reason: acquired by Roche)
9.50
0.00 (0.00%)
Inactive ยท Last trade price on Jan 7, 2025
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$457,145
Profits / Employee
-$184,118
Market Cap
928.85M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2023 | 330 | 16 | 5.10% | 330 | 0 |
| Dec 31, 2022 | 314 | 51 | 19.39% | 314 | 0 |
| Dec 31, 2021 | 263 | 57 | 27.67% | 263 | 0 |
| Dec 31, 2020 | 206 | 57 | 38.26% | 206 | 0 |
| Dec 31, 2019 | 149 | 97 | 186.54% | 149 | 0 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
PSTX News
- 1 year ago - Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - GlobeNewsWire
- 1 year ago - Roche to complete acquisition of U.S. biopharma company Poseida - Reuters
- 1 year ago - Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting - PRNewsWire
- 1 year ago - POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX - Business Wire
- 1 year ago - Poseida shares triple on Tuesday, boosted by Roche collaboration - Invezz
- 1 year ago - Why This Gene-Therapy Company's Stock Is Rising 228% - Barrons
- 1 year ago - Roche to acquire US-based Poseida Therapeutics - Reuters
- 1 year ago - Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies - GlobeNewsWire